A Lancet editorial discusses the agenda of the XIX International AIDS Conference (AIDS 2012) in Washington last month and asks how the success of the conference will be judged at the XX International AIDS Conference (AIDS 2014), to be held in Melbourne, Australia. “The return of the conference to the U.S. after 22 years, [was not only] a focus for celebration, but also provided a platform for vocal objection to the ban on injecting drug users and sex workers from entering the U.S.,” the editorial states, adding that “the absence of these groups from the meeting is rightly seen by many as a hindrance to developing approaches to combat the epidemic in regions where the disease is concentrated in these populations.”
The New York Times reports on efforts by the GAVI Alliance to deliver vaccines for children in war-torn and secretive countries. According to the newspaper, the non-profit group “sold to North Korea a vaccine against five diseases, and has announced plans to roll out other vaccines soon in Yemen, the Republic of Congo and Pakistan.” The newspaper notes that the alliance “does not do the vaccinating, but negotiates low prices from manufacturers and resells the vaccines at prices on a sliding scale, depending on a country’s gross national income per capita.” According to the New York Times, “[F]irst the group studies whether the country can use the vaccine — whether officials can keep it refrigerated even in rural villages, for example, and whether there are enough trained vaccinators” (McNeil, 7/30).
“In April, Partners In Health [PIH] responded to Haiti’s cholera epidemic by providing oral vaccinations to 45,000 people living in the country’s Artibonite region — specifically, to two rice-farming communities hit hard by cholera,” Louise Ivers, senior health and policy adviser at PIH, reports in an article on the organization’s webpage. “In partnership with Haiti’s Ministry of Health, hundreds of community health workers fanned out across the rural, flood-prone area, delivering two doses to each person by the end of May,” she writes, and discusses the impact of the campaign (8/1).
Using a rodent model to examine the long-term effects of a potential malaria vaccine, a new study published in PLoS Biology by researchers at Penn State University shows that the vaccine could lead to the development of more virulent forms of malaria, the PLoS blog “Biologue” reports (Gross, 7/31). “Vicki Barclay, the study’s lead author, said it shows a need to track the long-term impact of any malaria vaccine, especially since any such vaccine is expected to be ‘leaky’ — meaning it won’t offer complete protection, and the disease will continue to spread, albeit at a slower rate,” CNN’s “The Chart” writes. “Researchers working with the leading candidate vaccine immediately questioned [the study], saying they’ve seen no sign of dangerous changes as a result of their work,” the blog continues (Hellerman, 8/1).
In this post in BMJ’s “Yankee Doodling,” Douglas Kamerow, chief scientist at RTI International and an associate editor for the journal, reflects on the possibility of achieving an AIDS-free generation “if somehow we succeeded in getting all HIV positive people in the world identified and under long term treatment.” He writes that while there has been “astonishing progress against AIDS,” “two concerns immediately arise: the magnitude of the work remaining to find and continuously treat all those infected, and the confusion between that treatment (even if it is somehow universally successful) and actual eradication of the disease.” He concludes, “It is a rosy scenario, but even if it came true it still would not spell the end of the HIV story,” because “[w]e have no vaccine, and the virus keeps mutating” (8/14).
“When you’re dealing with a global public health crisis, having an international presence isn’t just advisable — it is imperative,” Margaret McGlynn, president and CEO of the International AIDS Vaccine Initiative (IAVI), writes in this post in USAID’s “Impact” blog, adding, “That’s why [IAVI], in partnership with USAID, has worked diligently over the past several years to establish itself as a truly global non-profit partner.” She continues, “IAVI has created an enviable network of research centers in sub-Saharan Africa dedicated to assessing novel AIDS vaccine candidates in clinical trials and conducting supporting epidemiological studies on HIV,” and writes that these “partnerships have made meaningful contributions to the research capacity of many developing countries — a capability that is now helping local researchers tackle other diseases” (8/13).
In its ongoing series examining efforts to eradicate polio, NPR health editor Joe Neel and Jason Beaubien, a global health and development correspondent for the news service, on Thursday spoke with “Talk of the Nation” host Neil Conan about obstacles to stamping out polio in the three countries where the disease persists — Afghanistan, Pakistan, and Nigeria. According to the transcript, they discuss how “[o]bstacles in each country, including religious extremism, difficult terrain and transient populations, make eradication efforts difficult” (10/25).
The Centers for Disease Control and Prevention (CDC) on Monday released a 268-page annual report that “profiles a wide range of CDC influenza-related projects around the world, from flu surveillance in Indonesia to vaccine effectiveness studies in El Salvador and epidemiology training in Ghana,” CIDRAP News reports. The report also “describes the CDC’s collaborations with the World Health Organization (WHO), outlines projects it supports in about 40 countries, … describes specific studies undertaken in many of those countries,” “lists international training conferences it has sponsored, and describes the CDC program for sharing diagnostic test kits and reagents,” the news service writes. “Over the past six years the [international] program has undergone remarkable growth and has expanded to provide support to over 40 countries, all WHO regional offices and WHO headquarters,” the report notes, according to CIDRAP. “The report, covering 2011, is the third annual account of the agency’s global flu activities, which have expanded greatly in the past decade,” the news service adds (Roos, 10/30).
UNICEF has released its 2012 partnership profiles, “short case studies which highlight specific partnership initiatives at global, regional and country levels” and “illustrate how partnerships have contributed to results, either the creation of innovation, policy advocacy, evidence generation, or provision of essential services,” according to UNICEF’s Partnerships webpage. Some of the organizations highlighted include the GAVI Alliance (.pdf), the Global Fund to Fight AIDS, Tuberculosis and Malaria (.pdf), and the Global Polio Eradication Initiative (.pdf) (9/17).
Bill Gates Describes How 'Catalytic Philanthropy' Can Help Bring Vaccines, Medicines To Untouched Markets
In an essay adapted for Forbes magazine from a speech given at the Forbes 400 Summit on Philanthropy in June, Bill Gates, co-chair of the Bill & Melinda Gates Foundation, discusses how “[i]nnovations for the poor suffer from … market limitations” and his idea of “catalytic philanthropy.” Gates writes, “The market is not going to place huge bets on research when there are no buyers for a breakthrough. This explains why we have no vaccine for malaria today, even though a million people die from it every year.” Therefore, “when you come to the end of the innovations that business and government are willing to invest in, you still find a vast, unexplored space of innovation where the returns can be fantastic,” he continues.